The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in Sage Therapeutics, Inc. (NASDAQ:SAGE) shares.<\/p>\n Investors who purchased shares of Sage Therapeutics, Inc. (NASDAQ:SAGE) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.<\/p>\n On August 28, 2024, an investor in NASDAQ: SAGE shares filed a lawsuit over alleged securities laws violations by Sage Therapeutics, Inc. The plaintiff alleged that the defendants made false and\/or misleading statements and\/or failed to disclose that zuranolone was less effective in treating MDD than Defendants had led investors to believe, that accordingly, the FDA was unlikely to approve the Zuranolone NDA for the treatment of MDD in its present form, and zuranolone’s clinical results for MDD, as well as its overall regulatory and commercial prospects, were overstated, that SAGE-718 was less effective in treating MCI due to PD than Defendants had led investors to believe, that accordingly, SAGE-718’s clinical, regulatory, and commercial prospects as a treatment for MCI due to PD were overstated, that SAGE-324 was less effective in treating ET than Defendants had led investors to believe, thataccordingly, SAGE-324’s clinical, regulatory, and commercial prospects as a treatment for ET were overstated, and that as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.<\/p>\n Those who purchased shares of Sage Therapeutics, Inc. (NASDAQ: SAGE) should contact the Shareholders Foundation, Inc.<\/p>\n CONTACT:<\/p>\n Shareholders Foundation, Inc. The Shareholders Foundation, Inc. is a professional portfolio legal monitoring and a settlement claim filing service, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock\/financial market. The Shareholders Foundation, Inc. is not a law firm. Any referenced cases, investigations, and\/or settlements are not filed\/initiated\/reached and\/or are not related to Shareholders Foundation. The information is only provided as a public service. It is not intended as legal advice and should not be relied upon. <\/p>\n Contact Information<\/strong><\/p>\n Michael Daniels
\n SAN DIEGO, CA, September 8, 2024 (Newswire.com)
\n –
\n <\/strong>A lawsuit is pending for certain investors in Sage Therapeutics, Inc. (NASDAQ:SAGE) shares. Investors in NASDAQ:SAGE shares should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554.<\/strong><\/i><\/p>\n![\"mail@shareholdersfoundation.com\"\/](\"https:\/\/www.accesswire.com\/imagelibrary\/1db34831-08c2-463f-b8d3-faa4899e2b90\/913806\/526160fd264c42e23ab2d1a54f48.jpg\")
<\/a>
Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 – 1554<\/figcaption><\/figure>\n
Michael Daniels
+1 (858) 779-1554
mail@shareholdersfoundation.com<\/a>
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108<\/p>\n
Manager<\/i>
mail@shareholdersfoundation.com<\/a>
858-779-1554 <\/p>\n